The Quantikine Human Follistatin Immunoassay is a 5.5 hour solid-phase ELISA designed to measure human Follistatin (FS288, FS300, and FS315) in follicular fluid, cell culture supernates, serum, and plasma. It contains Sf 21-expressed recombinant human Follistatin and antibodies raised against the recombinant factor. It has been shown to accurately quantitate recombinant human Follis...tatin. Results obtained using natural Follistatin showed linear curves that were parallel to the standard curves obtained using the Quantikine kit standards. These results indicate that this kit can be used to determine relative mass values for natural Follistatin.
Store the unopened product at 2 - 8 °C. Do not use past expiration date.
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for Human Follistatin Quantikine ELISA Kit
follistatin isoform FST317
Follistatin (FST) is a secreted glycoprotein that binds and neutralizes several TGF-beta superfamily proteins including Activin, BMP-6, BMP-7, and GDF-8/Myostatin. It also binds Angiogenin and regulates hematopoietic stem cell adhesion to Fibronectin. Some Follistatin binding partners will also bind Follistatin-like proteins such as FSL-3. Of three follistatin isoforms, the full-length mature follistatin (FST315) is the most abundant and the sole form in plasma, but has lower binding affinity for both activins and heparins than alternative forms. The acidic tail is missing in the splice variant FST288, which shows highest affinity, and partial in the proteolytically produced FST303, which shows intermediate affinity. Genetic deletion of follistatin in mice, or expression of only the FST288 form, is lethal perinatally due to defects of lung, skin and musculoskeletal system. Expression of only the FST315 isoform allows survival, with defects in vascularization and female fertility.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.